Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer

Guan,Xiaojiao; Zhong,Xinwen; Men,Wanfu; Gong,Shulei; Zhang,Lin; Han,Yuchen

doi:10.3892/mco.2013.207

Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer

Authors:
- Xiaojiao Guan
- Xinwen Zhong
- Wanfu Men
- Shulei Gong
- Lin Zhang
- Yuchen Han
View Affiliations

Affiliations: Department of Pathology, Basic Science College, China Medical University, Shenyang, Liaoning, P.R. China, Department of Thoracic Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, P.R. China
Published online on: October 24, 2013 https://doi.org/10.3892/mco.2013.207
Pages: 76-80

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy, requiring effective biomarkers for prognosis and therapeutic responsiveness. Histone H3K9 methyltransferases (EHMT1 and EHMT2) are global genome organizers, which are crucial for maintaining the balance state of cells in a tissue‑specific manner. It was previously suggested that EHMT1 expression is a predictor of prognosis in several malignant tumors; however, the prognostic significance of EHMT1 expression in ESCC has not been determined. A cohort of 50 ESCC cases and 46 paired normal esophageal tissue samples were evaluated to assess the levels of EHMT1 expression by immunohistochemistry and reverse transcription‑polymerase chain reaction. the SPSS software package was used for statistical data analysis. A significantly upregulated EHMT1 expression was observed in squamous preinvasive lesions and ESCC compared to the matched normal esophageal epithelia (52.0 vs. 21.7%, respectively). The expression of EHMT1 was correlated with tumor grade (G), depth of invasion (T) and lymph node metastasis (N) in ESCC. EHMT1 overexpression was found to be associated with poor cancer‑specific survival in squamous cell carcinomas (χ2=3.922, P=0.048). The expression of EHMT1 was identified as an independent prognostic factor for overall survival in ESCC patients. In conclusion, EHMT1 expression is upregulated in ESCC and early preinvasive esophageal squamous lesions and the overexpression of EHMT1 is associated with poor prognosis in ESCC. Therefore, the expression of EHMT1 may be an effective prognostic biomarker for ESCC.

View Figures

View References

1.	Thallinger CM, Kiesewetter B, Raderer M and Hejna M: Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res. 11:4609–4627. 2012.PubMed/NCBI
2.	Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H, Sakihama T, Kodama T, Hamakubo T and Shinkai Y: Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 19:815–826. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Collins R and Cheng X: A case study in cross-talk: the histone lysine methyltransferases G9a and GLP. Nucleic Acids Res. 38:3503–3511. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Chin HG, Esteve PO, Pradhan M, Benner J, Patnaik D, Carey MF and Pradhan S: Automethylation of G9a and its implication in wider substrate specificity and HP1 binding. Nucleic Acids Res. 35:7313–7323. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y, Shinkai Y, Cheng X and Jeltsch A: Protein lysine methyltransferase G9a acts on non-histone targets. Nat Chem Biol. 4:344–346. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ and Leutz A: G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem. 283:26357–26363. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Fritsch L, Robin P, Mathieu JR, et al: A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. Mol Cell. 37:46–56. 2010. View Article : Google Scholar : PubMed/NCBI
8.	Sampath SC, Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbrauker I, Viale A, Rudensky E, Zhou MM, Chait BT and Tarakhovsky A: Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Mol Cell. 27:596–608. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Lee SH, Kim J, Kim WH and Lee YM: Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells. Oncogene. 28:184–194. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Purcell DJ, Khalid O, Ou CY, et al: Recruitment of coregulator G9a by Runx2 for selective enhancement or suppression of transcription. J Cell Biochem. 113:2406–2414. 2012. View Article : Google Scholar : PubMed/NCBI
11.	Purcell DJ, Jeong KW, Bittencourt D, et al: A distinct mechanism for co-activator versus corepressor function by histone methytransferase G9a in transcriptional regulation. J Biol Chem. 286:41963–41971. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Bird A: Methylation talk between histones and DNA. Science. 294:2113–2115. 2001. View Article : Google Scholar : PubMed/NCBI
13.	Tamaru H, Zhang X, McMillen D, et al: Trimethylated lysine 9 of histone H3 is a mark for DNA methylation in Neurospora crassa. Nat Genet. 34:75–79. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Jackson JP, Lindroth AM, Cao X and Jacobsen SE: Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature. 416:556–560. 2002. View Article : Google Scholar : PubMed/NCBI
15.	Ikegami K, Iwatani M, Suzuki M, et al: Genome-wide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Gene Cells. 12:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Chen L, Li Z, Zwolinska AK, et al: MDM2 recruitment of lysine methyltransferases regulates p53 transcriptional output. EMBO J. 29:2538–2552. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Candelaria M, de la Cruz-Hernandez E, Taja-Chayeb L, et al: DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells. PloS One. 7:e291812010. View Article : Google Scholar : PubMed/NCBI
18.	Ibrahim AE, Arends MJ, Silva AL, Wyllie AH, Greger L, Ito Y, Vowler SL, Huang TH, Tavare S and Murrell A: Sequential DNA methylation changes are associated with DNMT2B over-expression in colorectal neoplastic progression. Gut. 60:499–508. 2010. View Article : Google Scholar : PubMed/NCBI
19.	Schwartzman J, Mongoue-Tchokote S, Gibbs A, et al: A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. Epigenetics. 6:1248–1256. 2011. View Article : Google Scholar
20.	Jelinek J, Gharibyan V, Estecio MR, et al: Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PloS One. 6:e221102011. View Article : Google Scholar : PubMed/NCBI